PHASE II STUDY OF ERLOTINIB AS A FIRST-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER PATIENTS ACCORDING TO THEIR CLINICAL PREDICTORS

被引：0
|
作者：
Lee, D. H. [1 ]
Kim, H. T. [2 ]
Kim, S. [1 ]
Suh, C. [1 ]
Lee, J. [1 ]
机构：
[1] Asan Med Ctr, Dept Internal Med, Div Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Ctr Lung Canc, Goyang, South Korea
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [11] A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
    Suzuki, R.
    Hasegawa, Y.
    Baba, K.
    Saka, H.
    Saito, H.
    Taniguchi, H.
    Yamamoto, M.
    Matsumoto, S.
    Kato, K.
    Oishi, T.
    Imaizumi, K.
    Shimokata, K.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1599 - 1603
  • [12] A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
    R Suzuki
    Y Hasegawa
    K Baba
    H Saka
    H Saito
    H Taniguchi
    M Yamamoto
    S Matsumoto
    K Kato
    T Oishi
    K Imaizumi
    K Shimokata
    British Journal of Cancer, 2006, 94 : 1599 - 1603
  • [13] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Saijo, N
    Nishiwaki, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 64 - 69
  • [14] Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
    Reck, Martin
    IMMUNOTHERAPY, 2018, 10 (02) : 93 - 105
  • [15] Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
    Raez, Luis E.
    Kobina, Svetlana
    Santos, Edgardo S.
    CLINICAL LUNG CANCER, 2010, 11 (01) : 18 - 24
  • [16] Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
    Mok, Tony S. K.
    Wu, Yi-Long
    Yu, Chong-Jen
    Zhou, Caicun
    Chen, Yuh-Min
    Zhang, Li
    Ignacio, Jorge
    Liao, Meilin
    Srimuninnimit, Vichien
    Boyer, Michael J.
    Chua-Tan, Marina
    Sriuranpong, Virote
    Sudoyo, Aru W.
    Jin, Kate
    Johnston, Michael
    Chui, Winsome
    Lee, Jin-Soo
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5080 - 5087
  • [17] Phase I/II Trial of Docetaxel and Carboplatin as a First-Line Therapy in Patients with Stage IV Non-Small-Cell Lung Cancer
    Kensuke Kataoka
    Ryujiro Suzuki
    Hiroyuki Taniguchi
    Yasunobu Noda
    Joe Shindoh
    Syuichi Matsumoto
    Yoshiaki Watanabe
    Kousuke Honda
    Kiyoshi Suzuki
    Kenji Baba
    Kazuyoshi Imaizumi
    Hiroaki Kume
    Yoshinori Hasegawa
    Kenzo Takagi
    Lung, 2006, 184 : 133 - 139
  • [18] Phase I/II trial of docetaxel and carboplatin as a first-line therapy in patients with stage IV non-small-cell lung cancer
    Kataoka, Kensuke
    Suzuki, Ryujiro
    Taniguchi, Hiroyuki
    Noda, Yasunobu
    Shindoh, Joe
    Matsumoto, Syuichi
    Watanabe, Yoshiaki
    Honda, Kousuke
    Suzuki, Kiyoshi
    Baba, Kenji
    Imaizumi, Kazuyoshi
    Kume, Hiroaki
    Hasegawa, Yoshinori
    Takagi, Kenzo
    LUNG, 2006, 184 (03) : 133 - 139
  • [19] First-Line Immunotherapy for Non-Small-Cell Lung Cancer
    Reck, Martin
    Remon, Jordi
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 586 - +
  • [20] Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer
    Twelves, C.
    Chmielowska, E.
    Havel, L.
    Popat, S.
    Swieboda-Sadlej, A.
    Sawrycki, P.
    Bycott, P.
    Ingrosso, A.
    Kim, S.
    Williams, J. A.
    Chen, C.
    Olszanski, A. J.
    de Besi, P.
    Schiller, J. H.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 132 - 138
12345